Synthesis of Tetrahydrohonokiol Derivates and Their Evaluation for Cytotoxic Activity against CCRF-CEM Leukemia, U251 Glioblastoma and HCT-116 Colon Cancer Cells

被引:16
作者
Bernaskova, Marketa [1 ]
Kretschmer, Nadine [2 ]
Schuehly, Wolfgang [2 ,3 ]
Huefner, Antje [1 ]
Weis, Robert [1 ]
Bauer, Rudolf [2 ]
机构
[1] Graz Univ, Inst Pharmaceut Sci, Dept Pharmaceut Chem, A-8010 Graz, Austria
[2] Graz Univ, Inst Pharmaceut Sci, Dept Pharmacognosy, A-8010 Graz, Austria
[3] Graz Univ, Inst Zool, A-8010 Graz, Austria
来源
MOLECULES | 2014年 / 19卷 / 01期
基金
奥地利科学基金会;
关键词
tetrahydrohonokiol derivatives; cytotoxicity; CCRF-CEM leukemia cells; U251; glioblastoma; HCT-116 colon cancer cells; Magnolia officinalis; IN-VITRO; NATURAL-PRODUCT; HONOKIOL; APOPTOSIS; GROWTH; ANGIOGENESIS; INHIBITION; MODULATION; NEOLIGNANS; POTENT;
D O I
10.3390/molecules19011223
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biphenyl neolignans such as honokiol and magnolol, which are the major active constituents of the Asian medicinal plant Magnolia officinalis, are known to exert a multitude of pharmacological and biological activities. Among these, cytotoxic and tumor growth inhibitory activity against various tumour cell lines are well-documented. To further elucidate the cytotoxic effects of honokiol derivatives, derivatizations were performed using tetrahydrohonokiol as a scaffold. The derivatizations comprised the introduction of functional groups, e. g., nitro and amino groups, as well as alkylation. This way, 18 derivatives, of which 13 were previously undescribed compounds, were evaluated against CCRF-CEM leukemia cells, U251 glioblastoma and HCT-116 colon cancer cells. The results revealed no significant cytotoxic effects in any of the three tested cell lines at a test concentration of 10 mu M.
引用
收藏
页码:1223 / 1237
页数:15
相关论文
共 36 条
[31]   Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells [J].
Shigemura, Katsumi ;
Arbiser, Jack L. ;
Sun, Shi-Yong ;
Zayzafoon, Majd ;
Johnstone, Peter A. S. ;
Fujisawa, Masato ;
Gotoh, Akinobu ;
Weksler, Babette ;
Zhau, Haiyen E. ;
Chung, Leland W. K. .
CANCER, 2007, 109 (07) :1279-1289
[32]   Antimetastatic activity of honokiol in osteosarcoma [J].
Steinmann, Patrick ;
Walters, Denise K. ;
Arlt, Matthias J. E. ;
Banke, Ingo J. ;
Ziegler, Urs ;
Langsam, Bettina ;
Arbiser, Jack ;
Muff, Roman ;
Born, Walter ;
Fuchs, Bruno .
CANCER, 2012, 118 (08) :2117-2127
[33]   Modulation of GABAA-Receptors by Honokiol and Derivatives: Subtype Selectivity and Structure-Activity Relationship [J].
Taferner, Barbara ;
Schuehly, Wolfgang ;
Huefner, Antje ;
Baburin, Igor ;
Wiesner, Katharina ;
Ecker, Gerhard F. ;
Hering, Steffen .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (15) :5349-5361
[34]  
Tang W., 1992, CHINESE DRUGS PLANT, P639
[35]   Honokiol Crosses BBB and BCSFB, and Inhibits Brain Tumor Growth in Rat 9L Intracerebral Gliosarcoma Model and Human U251 Xenograft Glioma Model [J].
Wang, Xianhuo ;
Duan, Xingmei ;
Yang, Guangli ;
Zhang, Xiaoyan ;
Deng, Linyu ;
Zheng, Hao ;
Deng, Chongyang ;
Wen, Jiaolin ;
Wang, Ning ;
Peng, Cheng ;
Zhao, Xia ;
Wei, Yuquan ;
Chen, Lijuan .
PLOS ONE, 2011, 6 (04)
[36]   Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor [J].
Widdowson, KL ;
Elliott, JD ;
Veber, DF ;
Nie, H ;
Rutledge, MC ;
McCleland, BW ;
Xiang, JN ;
Jurewicz, AJ ;
Hertzberg, RP ;
Foley, JJ ;
Griswold, DE ;
Martin, L ;
Lee, JM ;
White, JR ;
Sarau, HM .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1319-1321